News

News 2016-10-15T14:05:37+00:00
610, 2017

VLP Therapeutics Announces Phase 1 SBIR Grant Award From National Cancer Institute

2017.10.06|

VLP Therapeutics Announces Phase 1 SBIR Grant Award From National Cancer Institute Grant will support development of novel Virus-Like Particle vaccine-based cancer immunotherapy October 6, 2017 Gaithersburg, MD – VLP

2107, 2017

VLP Therapeutics Appoints Jacob Licht as Chief Operating Officer

2017.07.21|

Gaithersburg, Md. — July 21, 2017 — VLP Therapeutics, LLC (“VLP”), a biotechnology company focusing on the research and development of therapeutic and preventative vaccines and antibody agents, today announced

107, 2017

Clinical and Vaccine Immunology – July 2017, Volume 24, Issue 7

2017.07.01|

“Development of a Novel Virus-Like Particle Vaccine Platform That Mimics the Immature Form of Alphavirus” Akane Urakami, Atsuko Sakurai, Momoko Ishikawa, Moh Lan Yap, Yevel Flores-Garcia, Yasunari Haseda, Taiki Aoshi,

905, 2017

VLP Therapeutics Announces Convertible Note Investment from TomyK Ltd. for Accelerating Cancer Vaccine Development

2017.05.09|

Gaithersburg, Md. — May 9, 2017 — VLP Therapeutics, LLC (“VLP”), a biotechnology company focusing on the research and development of therapeutic and preventative vaccines and antibody agents, today announced

1904, 2017

VLP Therapeutics Receives Notice of Allowance of Key U.S. composition of matter Patent for immune checkpoint PD-1/PD-L1/PD-L2 inserted alphavirus VLP

2017.04.19|

Patent covers a composition of matter for immune checkpoint PD-1/PD-L1/PD-L2 inserted alphavirus VLP and method of use for cancer therapy Gaithersburg, Md. — April 19, 2017 — VLP Therapeutics, LLC.